Skip to main content

Table 2 Antibody response against PvAMA-1 at three sites in India

From: Antibody responses within two leading Plasmodium vivax vaccine candidate antigens in three geographically diverse malaria-endemic regions of India

Seroprevalence

Chennai

Nadiad

Rourkela

Total

n/N (%)

95% CI

n/N (%)

95% CI

n/N (%)

95% CI

n/N (%)

95% CI

Overall

31/66 (47.0)

35.0–59.3

43/92 (46.7)

36.6–57.1

21/76 (27.6)

18.6 –39.0

95/234 (40.6)

34.4–47.1

Gender

 Male

23/41 (56.1)

40.2–70.9

25/60 (41.7)

29.6–54.8

10/45 (22.2)

12.1–37.2

58/146 (39.7)

32.0–48.0

 Female

8/25 (32.0)

16.0–53.7

18/32 (56.2)

38.1–72.9

11/31 (35.5)

20.1–54.5

37/88 (42.0)

32.0–52.7

Age (years)

 < 15

0

0

7/20 (35.0)

16.4–59.6

3/25 (12.0)

03.6–33.3

10/45 (22.2)

12.1–37.2

 ≥ 15

31/66 (47.0)

35.0–59.3

36/72 (50.0)

38.4–61.6

18/51 (35.3)

23.1 –49.7

85/189 (45.0)

38.0–52.2

PCR

 Positive

23/37 (62.2)

45.0 –76.7

39/49 (79.6)

65.5–88.9

13/28 (46.4)

28.2–65.7

75/114 (65.8)

56.5–74.0

 Negative

8/29 (27.6)

13.1–47.5

4/43 (9.3)

03.4–23.0

8/48 (16.7)

08.3–30.5

20/120 (16.7)

10.9–24.5

Malaria

 Asymptomatic

18/28 (64.3)

44.1–80.4

21/27 (77.8)

57.0–90.2

11/25 (44.0)

25.2–64.7

50/80 (62.5)

51.2–72.6

 Symptomatic

5/9 (55.5)

19.5–86.6

18/22 (81.8)

58.1–93.6

2/3 (66.7)

0.3–99.9

25/34 (73.5)

55.4–86.1

Parasitaemia

 Low

19/25 (76.0)

54.1–89.5

28/35 (80.0)

62.6–90.5

5/10 (50.0)

18.1–81.9

52/70 (74.3)

62.5–83.3

 High

3/4 (75.0)

4.1–99.5

11/13 (84.6)

49.0–96.9

4/7 (57.1)

15.0–90.9

18/24 (75.0)

52.5–89.0

  1. CI confidence interval